<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663234</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT P1063</org_study_id>
    <secondary_id>U01AI068632</secondary_id>
    <secondary_id>10167</secondary_id>
    <nct_id>NCT00663234</nct_id>
  </id_info>
  <brief_title>IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia</brief_title>
  <official_title>Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of HIV with combination antiretroviral regimens frequently results in the
      suppression of HIV viral load, significant immune recovery, and delayed disease progression.
      However, treatment with these regimens, particularly protease inhibitors (PIs), has been
      associated with significant increases in cholesterol and triglycerides in HIV-infected adults
      and children. The purpose of this study was to evaluate the safety and effectiveness of
      escalating doses of atorvastatin, a FDA-approved drug which lowers cholesterol and
      triglyceride levels, in HIV-infected children receiving stable antiretroviral regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral regimens, particularly those containing PIs, often cause hyperlipidemia, which
      is an increase in the amount of fat (such as cholesterol and triglycerides) in the blood.
      These increases can lead to heart disease and pancreatitis. Although the mechanism by which
      PIs cause hyperlipidemia is not clearly understood, there are medications to combat this side
      effect. The primary purpose of this study was to evaluate the safety and effectiveness of
      escalating doses of atorvastatin, based on low-density lipoprotein cholesterol (LDL-C)
      levels, in HIV-infected children receiving stable antiretroviral therapy.

      Participants were assigned to one of two groups based on age (10 to 14 years or 15 to 23
      years) and were treated for a maximum of 48 weeks. The first six participants enrolled in the
      study were in the 15 to 23 year old age group. Once safety data through week 8 on these 6
      participants was analyzed, the remaining participants were enrolled. All participants
      received atorvastatin in combination with a stable antiretroviral regimen. Each participant
      was followed independently according to a dose escalation algorithm for atorvastatin.
      Participants began dosing at 10 mg daily. If efficacy criteria were not met, dosing increased
      to 20 mg daily at week 8. Since dose escalations were done within subject, safety and
      efficacy rates were presented for the dose-escalation strategy overall and not for individual
      doses. Atorvastatin was provided by the study, but antiretrovirals were not.

      Study visits occurred at study entry and weeks 4, 8, 12, 24, 36, and 48. Safety labs were
      collected at all study visits. Blood collection for lipid measurements occurred at weeks 4,
      12, 24 and 48.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely discontinued due to administrative reasons.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)</measure>
    <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
    <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Adverse Event (AE)</measure>
    <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
    <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Data Available)</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Per Protocol)</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria and Did Not Experience a Primary Safety Endpoint Attributable to Study Drug</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by Age Group</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by NNRTI Treatment</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
    <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in LDL Cholesterol (LDL-C) From Study Entry</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) by Age Group</measure>
    <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
    <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing at Least One Adverse Event (AE) by Age Group</measure>
    <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
    <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Fasting Total Cholesterol (TC) From Study Entry</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides (TG) From Study Entry</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in HDL-cholesterol (HDL-C) From Study Entry</measure>
    <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A1 (Apo A-1) From Study Entry</measure>
    <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B (Apo B) From Study Entry</measure>
    <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-sensitivity CRP (Hs-CRP) From Study Entry</measure>
    <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Interleukin 6 (IL-6) From Study Entry</measure>
    <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Undetectable Plasma HIV-1 RNA</measure>
    <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
    <description>Undetectable is defined as plasma HIV-1 RNA below the lower limit of quantification of the assay used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Age 10 to 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 15 to 23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
    <arm_group_label>Age 10 to 14</arm_group_label>
    <arm_group_label>Age 15 to 23</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of HIV-1 infection

          -  CD4 % of at least 15 at screening

          -  HIV-1 viral load of less than 10,000 copies/ml at screening

          -  On a stable antiretroviral therapy regimen for at least 6 months

          -  Tanner stage of 2 or higher

          -  At least two LDL-C measurements of 130 mg/dL or higher over the 6 months prior to
             screening and after documented attempts at modifying diet and other risk factors. More
             information on this criterion can be found in the protocol.

          -  Able to fast overnight for 8 hours

          -  Negative pregnancy test at screening

          -  Agree to use two appropriate forms of contraception (female participants). More
             information on this criterion can be found in the protocol.

        Exclusion Criteria:

          -  Certain abnormal laboratory values

          -  Any laboratory or unresolved clinical toxicity of Grade 3 or higher

          -  Unlikely to remain on current antiretroviral therapy for at least six months after
             study entry

          -  Use of statin, fibrate, or niacin within 3 months prior to study entry

          -  Evidence of chronic ongoing myositis or history of myopathy or neuromuscular disorder

          -  Symptomatic peripheral neuropathy within 6 months prior to study entry

          -  Pharmacologic treatment for depression or other mental disorder excluding Attention
             Deficit Disorder within 30 days prior to study entry

          -  Presence of an active CDC Stage C opportunistic infection or serious bacterial
             infection requiring therapy within 2 weeks prior to screening.

          -  Chemotherapy for malignancy within 3 months prior to study entry

          -  Hepatitis B Surface Antigen positive

          -  Hepatitis C viremia

          -  Insulin-dependent diabetes mellitus

          -  Required treatment with an agent contraindicated with either atorvastatin or PIs. More
             information on this criterion can be found in the protocol.

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Melvin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Crain, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS (5052)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami Ped. Perinatal HIV/AIDS CRS (4201)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Tampa (5018)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Children's CRS (4001)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University (5095)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Ped. HIV Program NICHD CRS (5011)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hospital IMPAACT CRS (6901)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University NY (5012)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital (5003)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS (6501)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS (3801)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <reference>
    <citation>Kamin D, Hadigan C. Hyperlipidemia in children with HIV infection: an emerging problem. Expert Rev Cardiovasc Ther. 2003 May;1(1):143-50. Review.</citation>
    <PMID>15030304</PMID>
  </reference>
  <reference>
    <citation>Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.</citation>
    <PMID>14727985</PMID>
  </reference>
  <reference>
    <citation>Solórzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G, Vázquez Rosales G, Miranda Novales MG. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res. 2006 Jan;37(1):129-32.</citation>
    <PMID>16314198</PMID>
  </reference>
  <reference>
    <citation>The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009)</citation>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>December 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2016</results_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between August 31, 2009 (date first participant enrolled) and December 16, 2013 (date last participant enrolled).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage starts at 10 mg and is increased to 20 mg at week 8 if efficacy criteria is not met at week 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose Increased to 20 mg at Week 8</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not willing to adhere to requirements</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who initiated Atorvastatin were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 - &lt;15 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 - &lt;19 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19 - &lt;24 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Regardless of Race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Percent at screening, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>15% to &lt;25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA, Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=Lower limit of quantification of assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;Lower limit of quantification of assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antiretroviral (ARV) Regimen at entry, Categorical</title>
          <description>ARV regimens are categorized based on whether or not they contain Protease Inhibitors (PIs) and/or Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>At least one PI and at least one NNRTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one PI and no NNRTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NNRTI and no PI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other ARV regimen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)</title>
        <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
        <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)</title>
          <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
          <population>All participants who initiated Atorvastatin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="1.3" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing at Least One Adverse Event (AE)</title>
        <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
        <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least One Adverse Event (AE)</title>
          <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
          <population>All participants who initiated Atorvastatin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="9.8" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="9.8" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="15.1" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="43.5" upper_limit="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="30.1" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="40.0" upper_limit="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" lower_limit="36.6" upper_limit="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Data Available)</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated study treatment and have LDL-C data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Data Available)</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who initiated study treatment and have LDL-C data available at study entry and the specified week.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="45.3" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="31.3" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="43.6" upper_limit="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="39.8" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Per Protocol)</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who completed the study per protocol (initiated study drug, had LDL-C data available at all required study visits, attended study visits within the protocol-specified window, were dose-escalated according to protocol, and reported adherence to study drug at all study visits).</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Per Protocol)</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who completed the study per protocol (initiated study drug, had LDL-C data available at all required study visits, attended study visits within the protocol-specified window, were dose-escalated according to protocol, and reported adherence to study drug at all study visits).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="42.7" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="42.7" upper_limit="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="59.0" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" lower_limit="28.7" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria and Did Not Experience a Primary Safety Endpoint Attributable to Study Drug</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and did not experience a primary safety event attributable to Atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria and Did Not Experience a Primary Safety Endpoint Attributable to Study Drug</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who initiated Atorvastatin and did not experience a primary safety event attributable to Atorvastatin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="39.8" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="32.7" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" lower_limit="39.8" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" lower_limit="36.2" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by Age Group</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
        <group_list>
          <group group_id="O1">
            <title>10 to 14 Years Old</title>
            <description>Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
          <group group_id="O2">
            <title>15 to 23 Years Old</title>
            <description>Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by Age Group</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="34.1" upper_limit="94.7"/>
                    <measurement group_id="O2" value="57.1" lower_limit="37.2" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="5.3" upper_limit="65.9"/>
                    <measurement group_id="O2" value="52.4" lower_limit="32.8" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="34.1" upper_limit="94.7"/>
                    <measurement group_id="O2" value="52.4" lower_limit="32.8" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="34.1" upper_limit="94.7"/>
                    <measurement group_id="O2" value="47.6" lower_limit="28.6" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by NNRTI Treatment</title>
        <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
        <group_list>
          <group group_id="O1">
            <title>NNRTI-exposed</title>
            <description>Participant was on at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) at entry.</description>
          </group>
          <group group_id="O2">
            <title>NNRTI-unexposed</title>
            <description>Participant was not on at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) at entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by NNRTI Treatment</title>
          <description>Efficacy was defined as having LDL-C of 110 mg/dL or less or at least 30% decline in LDL-C from baseline to the specified week.</description>
          <population>All participants who initiated Atorvastatin. If a participant was missing data at a given week, treatment was assumed to be non-efficacious at that week.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="34.5" upper_limit="90.2"/>
                    <measurement group_id="O2" value="57.9" lower_limit="36.8" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="25.1" upper_limit="83.1"/>
                    <measurement group_id="O2" value="42.1" lower_limit="23.0" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="16.9" upper_limit="74.9"/>
                    <measurement group_id="O2" value="63.2" lower_limit="41.8" upper_limit="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="25.1" upper_limit="83.1"/>
                    <measurement group_id="O2" value="52.6" lower_limit="32.0" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in LDL Cholesterol (LDL-C) From Study Entry</title>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had LDL-C data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL Cholesterol (LDL-C) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had LDL-C data available at study entry and the specified week.</population>
          <units>percentage of LDL-C at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in LDL-C at Week 4 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" lower_limit="-34.6" upper_limit="-26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in LDL-C at Week 12 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" lower_limit="-32.4" upper_limit="-20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in LDL-C at Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" lower_limit="-32.7" upper_limit="-23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in LDL-C at Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" lower_limit="-33.1" upper_limit="-19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Fasting Total Cholesterol (TC) From Study Entry</title>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had total cholesterol data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Fasting Total Cholesterol (TC) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had total cholesterol data available at study entry and the specified week.</population>
          <units>percentage of TC at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in TC at Week 4 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" lower_limit="-26.8" upper_limit="-20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TC at Week 12 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" lower_limit="-25.1" upper_limit="-17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TC at Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" lower_limit="-26.0" upper_limit="-19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TC at Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.5" lower_limit="-26.4" upper_limit="-16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides (TG) From Study Entry</title>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had triglycerides data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides (TG) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had triglycerides data available at study entry and the specified week.</population>
          <units>percentage of TG at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in TG at Week 4 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" lower_limit="-20.4" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TG at Week 12 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" lower_limit="-19.5" upper_limit="-5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TG at Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" lower_limit="-22.8" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in TG at Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" lower_limit="-22.5" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in HDL-cholesterol (HDL-C) From Study Entry</title>
        <time_frame>Study entry and weeks 4, 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had HDL-C data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-cholesterol (HDL-C) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had HDL-C data available at study entry and the specified week.</population>
          <units>percentage of HDL-C at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in HDL-C at Week 4 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-2.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in HDL-C at Week 12 (N=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="-1.1" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in HDL-C at Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-3.1" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in HDL-C at Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-3.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A1 (Apo A-1) From Study Entry</title>
        <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had Apo A-1 data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein A1 (Apo A-1) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had Apo A-1 data available at study entry and the specified week.</population>
          <units>percentage of Apo A-1 at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in Apo A-1 at Week 12 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-3.2" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in Apo A-1 at Week 24 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-2.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in Apo A-1 at Week 48 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-4.8" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B (Apo B) From Study Entry</title>
        <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had Apo B data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B (Apo B) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had Apo B data available at study entry and the specified week.</population>
          <units>percentage of Apo B at study entry</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in Apo B at Week 12 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" lower_limit="-32.0" upper_limit="-22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in Apo B at Week 24 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" lower_limit="-29.5" upper_limit="-20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in Apo B at Week 48 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" lower_limit="-30.5" upper_limit="-17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-sensitivity CRP (Hs-CRP) From Study Entry</title>
        <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had hs-CRP data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-sensitivity CRP (Hs-CRP) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had hs-CRP data available at study entry and the specified week.</population>
          <units>percentage of hs-CRP at study entry</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in hs-CRP at Week 12 (N=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-35" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in hs-CRP at Week 24 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" lower_limit="-67" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in hs-CRP at Week 48 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-78" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Interleukin 6 (IL-6) From Study Entry</title>
        <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin and had IL-6 data available at study entry and the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Interleukin 6 (IL-6) From Study Entry</title>
          <population>All participants who initiated Atorvastatin and had IL-6 data available at study entry and the specified week.</population>
          <units>percentage of IL-6 at study entry</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in IL-6 at Week 12 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-32" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in IL-6 at Week 24 (N=23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19" lower_limit="-32" upper_limit="-5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in IL-6 at Week 48 (N=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" lower_limit="-34" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Undetectable Plasma HIV-1 RNA</title>
        <description>Undetectable is defined as plasma HIV-1 RNA below the lower limit of quantification of the assay used.</description>
        <time_frame>Study entry and weeks 12, 24, and 48</time_frame>
        <population>All study participants who initiated Atorvastatin and had HIV-1 RNA data available at the specified week.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Undetectable Plasma HIV-1 RNA</title>
          <description>Undetectable is defined as plasma HIV-1 RNA below the lower limit of quantification of the assay used.</description>
          <population>All study participants who initiated Atorvastatin and had HIV-1 RNA data available at the specified week.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (N=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="54.0" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="51.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="44.0" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="51.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) by Age Group</title>
        <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
        <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>10 to 14 Years Old</title>
            <description>Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
          <group group_id="O2">
            <title>15 to 23 Years Old</title>
            <description>Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) by Age Group</title>
          <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the core study team. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
          <population>All participants who initiated Atorvastatin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.7" upper_limit="52.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.7" upper_limit="52.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="5.3" upper_limit="65.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing at Least One Adverse Event (AE) by Age Group</title>
        <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
        <time_frame>Study entry to weeks 12, 24, and 48</time_frame>
        <population>All participants who initiated Atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>10 to 14 Years Old</title>
            <description>Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
          <group group_id="O2">
            <title>15 to 23 Years Old</title>
            <description>Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
Atorvastatin: 10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing at Least One Adverse Event (AE) by Age Group</title>
          <description>AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. The primary outcome measure includes any AE of grade 3 or higher and liver function tests (LFTs) of grade 2 or higher.</description>
          <population>All participants who initiated Atorvastatin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.7" upper_limit="52.1"/>
                    <measurement group_id="O2" value="23.8" lower_limit="9.9" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.7" upper_limit="52.1"/>
                    <measurement group_id="O2" value="23.8" lower_limit="9.9" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="5.3" upper_limit="65.9"/>
                    <measurement group_id="O2" value="28.6" lower_limit="13.2" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of Atorvastatin initiation until Week 48.</time_frame>
      <desc>The DAIDS Adverse Event (AE) Grading Table (Version 1.0) was used for grading of AEs. Expedited adverse event reporting followed Version 2.0 of the DAIDS Expedited Adverse Event Manual.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Target enrollment was 40 participants (20 in each age cohort). However, the study was prematurely discontinued due to administrative reasons, having enrolled only 28 participants (21 participants aged 10 to 14 and 7 participants aged 15 to 23).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

